What is ClinSpec DX?
ClinSpec DX is a Glasgow-based biotechnology firm established in 2016. The company specializes in developing blood serum testing solutions that utilize infra-red light and serum diagnostics for the early detection of critical diseases, including brain cancer. By focusing on non-invasive diagnostic methods, ClinSpec DX aims to revolutionize early disease identification, potentially improving patient outcomes and reducing healthcare burdens. The company's technological foundation is built upon advanced spectral analysis, enabling the identification of disease biomarkers in blood serum.
How much funding has ClinSpec DX raised?
ClinSpec DX has raised a total of $7.3M across 2 funding rounds:
Unspecified
$3.1M
Angel/Seed
$4.2M
Unspecified (2020): $3.1M with participation from SIS Ventures, Mercia, University of Strathclyde Glasgow, EoS Advisory, and Scottish Investment Bank
Angel/Seed (2021): $4.2M led by Scottish Enterprise, Mercia Group, SIS Ventures, Norcliffe Capital Limited, and University of Strathclyde Glasgow
Key Investors in ClinSpec DX
SIS Ventures
SIS Ventures is an investment firm that likely focuses on supporting innovative companies with significant growth potential, providing capital to fuel expansion and technological advancement.
Mercia
Mercia is an investment company that provides capital and support to businesses, likely with a focus on technology and innovation sectors, aiding in their development and scaling.
University of Strathclyde Glasgow
The University of Strathclyde Glasgow is a leading technological university that actively engages in research and industry partnerships, investing in ventures that align with its academic and innovation goals.
What's next for ClinSpec DX?
The recent major strategic investment positions ClinSpec DX for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development, enhance clinical validation processes, and scale up manufacturing capabilities. The company's focus on early detection of high-impact diseases like brain cancer aligns with a growing global demand for advanced diagnostic tools. ClinSpec DX's strategic partnerships and ongoing innovation efforts suggest a strong potential for future expansion and the establishment of its technology as a standard in diagnostic medicine. The company's trajectory indicates a move towards broader clinical adoption and commercialization.
See full ClinSpec DX company page
